EP
REGN icon

Edgestream Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Edgestream Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.66M Buy
+4,258
New +$2.9M 0.08% 445
2026
Q1 		– Sell
-4,591
Closed -$3.54M – 1069
2025
Q4 		$3.54M Sell
4,591
-4,294
-48% -$2.92M 0.1% 369
2025
Q3 		$5M Sell
8,885
-1,488
-14% -$841K 0.15% 251
2025
Q2 		$5.45M Buy
10,373
+8,124
+361% +$4.53M 0.15% 275
2025
Q1 		$1.43M Sell
2,249
-6,573
-75% -$4.52M 0.05% 550
2024
Q4 		$6.28M Buy
8,822
+8,475
+2,442% +$7.11M 0.27% 90
2024
Q3 		$365K Sell
347
-4,870
-93% -$5.42M 0.02% 743
2024
Q2 		$5.48M Sell
5,217
-2,422
-32% -$2.35M 0.26% 99
2024
Q1 		$7.35M Buy
+7,639
New +$7.26M 0.37% 34
2023
Q4 		– Sell
-1,297
Closed -$1.07M – 1027
2023
Q3 		$1.07M Buy
1,297
+457
+54% +$359K 0.09% 380
2023
Q2 		$604K Buy
+840
New +$648K 0.05% 489
2023
Q1 		– Sell
-295
Closed -$213K – 629
2022
Q4 		$213K Sell
295
-6,351
-96% -$4.69M 0.02% 473
2022
Q3 		$4.58M Buy
6,646
+2,155
+48% +$1.36M 0.35% 88
2022
Q2 		$2.65M Buy
4,491
+815
+22% +$530K 0.21% 164
2022
Q1 		$2.57M Buy
+3,676
New +$2.33M 0.2% 167
2021
Q4 		– Sell
-1,588
Closed -$961K – 567
2021
Q3 		$961K Buy
+1,588
New +$986K 0.06% 323
2020
Q4 		– Sell
-4,764
Closed -$2.67M – 412
2020
Q3 		$2.67M Buy
+4,764
New +$2.89M 0.17% 169

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Edgestream Partners's REGN Position: Q2 2026 in Review

Edgestream Partners opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 4,258 shares worth $2.66M. The stake represents 0.08% of the portfolio and ranks #445 among its holdings. This is a return to the name: Edgestream Partners previously reported a position in REGN as recently as Q4 2025.

Edgestream Partners first reported a position in REGN in Q3 2020 and has held it in 17 quarters since. The position peaked at $7.35M in Q1 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Edgestream Partners held 4,258 shares of Regeneron Pharmaceuticals worth $2.66M as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Edgestream Partners position in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.08% of Edgestream Partners's portfolio in Q2 2026, its #445 holding.
  • Edgestream Partners first reported a position in Regeneron Pharmaceuticals in Q3 2020 and has held it in 17 quarters since.
  • Edgestream Partners's Regeneron Pharmaceuticals position peaked at $7.35M in Q1 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.